Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT plus Concurrent Cisplatin vs IMRT Alone in Recurrent Nasopharyngeal Carcinoma
NCT04136886Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 3 years. Started Jan 2020; status: recruiting.
02
Drugs
cisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04136886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136886.